Omeros Corporation (OMER)

Market Cap	398.90M
Revenue (ttm)	n/a
Net Income (ttm)	-156.82M
Shares Out	58.06M
EPS (ttm)	-2.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	498,226
Open	6.96
Previous Close	6.99
Day's Range	6.66 - 7.20
52-Week Range	2.97 - 13.60
Beta	2.35
Analysts	Buy
Price Target	22.50 (+227.51%)
Earnings Date	May 14, 2025

About OMER

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2009
• Employees: 202
• Stock Exchange: NASDAQ
• Ticker Symbol: OMER
• Website: https://www.omeros.com

Analyst Forecast

According to 4 analysts, the average rating for OMER stock is "Buy." The 12-month stock price forecast is $22.5, which is an increase of 227.51% from the latest price.

Price Target

$22.5

(227.51% upside)

Analyst Consensus: Buy